
ãã¡ã€ã¶ãŒãšFDAã¯ã2021幎2æã«COVIDã¯ã¯ãã³ãå ç«æå¶ãšVAED/ADEãåŒãèµ·ããããšãç¥ã£ãŠãããããã人ã ãæ®ºããŠããããšãç¥ã£ãŠããŸããã
2022幎4æ1æ¥ãç±³é£åå»è¬åå±ïŒFDAïŒã«ããããã¡ã€ã¶ãŒç€Ÿã®ææž1äž1000ä»¶ããŸãããå ¬éãããããã¡ã€ã¶ãŒã®è©ŠéšããŒã¿ãããèªç¶å ç«ã¯ãžã£ããšåçã®å¹æãããããšã泚å°ã®å¯äœçšã¯55æ³ä»¥äžã§ããæ·±å»ã§ããããšãæããã«ãªã£ãã
ãŸãããã¡ã€ã¶ãŒç€Ÿã®åææžã«ã粟åãèå ãæä¹³äžã®åäŸãžã®åœ±é¿ã¯äžæããšæèšãããŠããããšãææžããæããã«ãªã£ããããããä¿å¥åœå±ãã¡ãã£ã¢ã¯ããã®æ³šå°ãçæ®ã«é¢ããå¥åº·ãçæ®èœåã«åœ±é¿ãäžããããšã¯ãªããåŠåš äžãæä¹³äžã®æ¯èŠªã«ãšã£ãŠãå®å šã«å®å šã§ããããšããäºå®ããšããŠä¿¡å¥ããŠããã®ã§ããã
ãã¡ã€ã¶ãŒç€ŸãšFDAã¯ããããã幎霢局ã®äººã ããååæäžåŸ1é±éã¯äžéæ§ã®å ç«æ©èœæå¶ãçµéšããããšãç¥ã£ãŠããã
ããããäœãããè¡æçãªã®ã¯ããã¡ã€ã¶ãŒã®ææžããæäœäŸåæ§å¢åŒ·ã®ãªã¹ã¯ãæé€ããŠããªãããšã瀺ããŠããããšã ãããã¯ã¯ãã³é¢é£åŒ·ååçŸæ£ïŒVAEDïŒã¯ãéèŠãªæœåšãªã¹ã¯ããšããŠèšèŒãããŠããã2021幎2æ28æ¥çŸåšããã¡ã€ã¶ãŒã«ã¯VAEDã®çãããã138äŸãããããã®ãã¡75äŸã¯å ¥é¢ãé害ãçåœãè ããçµæãŸãã¯æ»äº¡ã«è³ãéçäŸãåèš38äŸã¯èŽæ»ã65äŸã¯æªè§£æ±ºã§ãã£ãã
Jã»ã¡ã«ã³ã©å士è
2022幎4æ1æ¥ã«å ¬éããããã¡ã€ã¶ãŒç€Ÿã®ææž11,000ä»¶ã®æ°ããªãããã«ãã£ãŠãå€ãçæãæ°ããªæ¯æãåŸãããšã«ãªã£ããã©ã€ãžã³ã°ãã®å ±åãã¹ãã§ãããã ã»ã¢ã€ããŒã»ã³ïŒäžã®ãããªïŒãå ±åããããã«ãæåã®ç匟çºèšã¯ãèªç¶å ç«ã«ã¯å¹æãããããã¡ã€ã¶ãŒã¯ããããã£ãšç¥ã£ãŠãããšããããšã§ããã
èšåºè©Šéšã®ããŒã¿ã§ã¯ãCOVIDã«ææããããšã®ããäººãšæ³šå°ããã人ã®éã«è»¢åž°ã®å·®ã¯ãªãã£ããã©ã¡ãã®ã°ã«ãŒããéç¯€ãªææçãçµéšããªãã£ãããŸããèªç¶å ç«ãææã®ãªã¹ã¯ãšããç¹ã§ã¯ã泚å°ãšçµ±èšçã«åãã§ããã
è¥å¹Žå±€ã»ã©å¯äœçšãçµéšãã確çãé«ã
2ã€ç®ã®çºèŠã¯ã泚å°ã«ããå¯äœçšã¯ã55æ³ä»¥äžã®äººããã18æ³ãã55æ³ã®è¥ãäººã®æ¹ãããæ·±å»ã ã£ããšããããšã§ãã(å¯äœçšã®ãªã¹ã¯ãæäžåæ°ãå¢ããã»ã©é«ããªãã®ã§ã1åç®ãã2åç®ä»¥éã®æ¹ããªã¹ã¯ãé«ã)ã
ç§ãã¡ã®å€ãããã£ãšèšã£ãŠããããã«ãé床ã®COVIDã®ãªã¹ã¯ã¯60æ³ä»¥äžã®äººãããè¥ãäººã®æ¹ãåçã«äœãã®ã§ãå¯äœçšã®ãªã¹ã¯ã®äžæã¯åãå ¥ãããããã®ãªã®ã§ãã
The Naked Emperor on Substackãææããããã«1ã"è¥å¹Žå±€ã§ããé »ç¹ã«ãããæ·±å»ãªåå¿ãæå®³äºè±¡ãçã¿åºããŠããã¯ã¯ãã³ã§ã¯ãã¯ã¯ãã³ã¯å®éã«é床ã®COVID-19ã®ãªã¹ã¯ããã人ã«éå®ãããã¹ãã§ããã"
ãã¡ã€ã¶ãŒç€Ÿã®è³æã§å¿ççã®çºççãé«ãããšã倿
è峿·±ãããšã«ããã¡ã€ã¶ãŒã®ææžã«ã¯ãäž»èŠã¡ãã£ã¢ããã¡ã¯ããã§ãã«ãŒãèª€å ±ãŸãã¯åœæ å ±ãšã¬ããã«ã貌ã£ãå»çæ å ±ãå«ãŸããŠãããå°å çšã®åææžã«ã¯ãå¿ççã10äžäººã«1人ïŒã€ãŸã10äžäººã«2人ïŒã§ãããªã©ãããã€ãã®å¯äœçšã®å¯èœæ§ãèšèŒãããŠããã以åã«å ±åããã5äžäººã«1人ã®å²åããã¯ããã«å€ãã
ãŸããå¿ççã¯è¥ãç·æ§ã«å€ãèŠãããããšãåãã£ãŠããããã®ãããªå·å®³ã®å€§éšåãå ããè¥ãç·æ§ã«ãšã£ãŠã¯ããªã¹ã¯ã¯10äžåã®1ããããªãé«ããªããŸãã
ãªãããã¯ãã£ãã»ãã«ã¹ãžã®åœ±é¿ã¯äžæã§ã
ãŸããåææžã«ã¯ã粟åãèå ãæä¹³äžã®åäŸãžã®åœ±é¿ã¯äžæãšæèšãããŠããŸããããããä¿å¥åœå±ãã¡ãã£ã¢ã¯ããã®æ³šå°ãçæ®ã«é¢ããå¥åº·ãçæ®èœåã«åœ±é¿ãäžããããšã¯ãªããåŠç£å©Šã«ãšã£ãŠå®å šã«å®å šã§ããããšããäºå®ããšããŠä¿¡å¥ããŠããã
广ãäžæã§ããã°ãç¡å®³ã§ãããšäž»åŒµããããšã¯ã§ããªããçŸç 管çäºé²ã»ã³ã¿ãŒã®ããã·ã§ã«ã»ã¯ã¬ã³ã¹ããŒæé·ããã®äžäººã§ããã圌女ã¯ç¹°ãè¿ãããžã£ãã¯åŠå©Šãšãã®èµ€ã¡ããã«å¥åº·è¢«å®³ãäžããªããšæèšããŠããã2021幎5æã®ã¯ã¬ã³ã¹ããŒã§ãã
ãããŠã2021幎10æã圌女ã¯ãŸã ãªã¹ã¯ã¯ãªããšäž»åŒµããŠããã
åæ§ã«ãã³ãããã£ãèªå¯ããã2021幎8æãåœç«ã¢ã¬ã«ã®ãŒææçç ç©¶æã®ã¢ã³ãœããŒã»ãã¡ãŠãæé·ã¯ãCOVIDãžã£ãã¯åŠåš äžã§ãå®å šã§ãããšäž»åŒµããŠããŸãã
ç±³åœç£ç§å©Šäººç§åŠäŒïŒACOGïŒãå®å šæ§ã«ã€ããŠæå®çãªçºèšãããŠããã"ã¯ã¯ãã³æ¥çš®ã¯ã©ã®ããªã¡ã¹ã¿ãŒã§ãå¯èœã§ãããæ¯äœãšèå ã®å¥åº·ãæå€§åããããã«ã§ããã ãæ©ãã¯ã¯ãã³ãåãåãããšãéèŠãã¹ãã§ãã "ãšäž»åŒµããŠããŸã2ã ããããã³ãããã£ã®ã©ãã«3ïŒ4ã«ãã "åŠå©Šã«æäžããã³ãããã£ã«é¢ããå©çšã§ããããŒã¿ã¯åŠåš äžã®ã¯ã¯ãã³é¢é£ãªã¹ã¯ãç¥ãããã«ã¯äžååã§ãã "ãšèšèŒãããŠããã®ã§ãã
æäœäŸåæ§ã®å¢åŒ·ã¯åŠå®ãããŠããªã
mRNA泚å°ãæäœäŸåæ§å¢åŒ·ïŒADEïŒ-çµå±ãããã§ãªãå Žåãããæ·±å»ãªææçã«ãããããããªãç¶æ³-ãåŒãèµ·ããå¯èœæ§ã«ã€ããŠèŠåããå€ãã®äººã ã¯ãã¡ãã£ã¢ããäžå·ãæªè æ±ããããåœæ å ±æ¡æ£è ãšããã¬ããã«ã貌ãããŠããŸããã
ãããããã¡ã€ã¶ãŒç€Ÿèªèº«ã®åææžã«ã¯ã¯ã£ãããšããæžãããŠããã"çŸåšãŸã§ã®ãšããèŠãããªãããç ç©¶ãããã¯ã¯ãã³ãåŸã®COVID-19ã®ç æ°ãããéçåãããå¯èœæ§ã¯ãŸã åŠå®ã§ããªãã" Iversenãææããããã«ãããADEãæ¬åœã«å šãå¿é ãªãã®ã§ããã°ãåææžã«ã¯èšèŒããªãã¯ãã§ãããããããããã«ã¯ãããããã
ã¯ã¯ãã³é¢é£åŒ·åçŸæ£ïŒVAEDïŒã¯ãã5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reportsããšããææžã®11ããŒãžã®è¡š5ã«ããéèŠãªæœåšçãªã¹ã¯ããšããŠèšèŒãããŠããŸã5ã
2021幎2æ28æ¥æç¹ã§ããã¡ã€ã¶ãŒã¯VAEDã®çãã®ãã138ä»¶ã®çäŸãæã¡ããã®ãã¡75ä»¶ã¯å ¥é¢ãé害ãçåœãè ããçµæãŸãã¯æ»äº¡ã«è³ãéçã§ãããåèš38ä»¶ãèŽæ»ãšå€æã65ä»¶ã¯æªè§£æ±ºãšãªã£ãŠããŸã6,7ã
ããã«ãDaily Exposeãææããããã«8ãã第3çžèšåºè©Šéšã¯ãADEãå«ãã¯ã¯ãã³ã®äœ¿çšãæ¿èªãããåã«ãé »åºŠã®é«ãå¯äœçšãé節ãªå¯äœçšãçºèŠããããã®ãã®ã§ããããããããããã«åé¡ãããã"COVID-19ã¯ã¯ãã³ã¯ã©ãã第3çžèšåºè©Šéšãå®äºããŠããªãã®ã ã
ãã¡ã€ã¶ãŒã®ç¬¬3çžè©Šéšã¯20249幎2æ8æ¥ã«å®äºããäºå®ã§ãããä»ããçŽ2幎åŸã§ã ã«ããããããããã¡ã€ã¶ãŒã¯FDAã®ç³è«æžã§ã"75äŸã®ãã¡ãVAEDãšæ±ºå®çã«èãããããã®ã¯ãªã "ãšçµè«ä»ããŠããŸãã
"ãã£ããã©ãããŠãå ±åããããçªç Žå£ãäºäŸã®75ïŒ ãå ¥é¢ãé害ãçåœãè ããæ»ã«è³ãéçã§ãã£ãã®ã«ãVAEDãåå ã§ãããšæ±ºå®çã«çµè«ã¥ããããªãã£ãã®ã§ããããïŒ" ãšãThe Daily Exposeãã¯åããããŠãã10ã
ãã¡ã€ã¶ãŒã¯å ç«æå¶ã«ã€ããŠç¥ã£ãŠãã
ããäžã€ãè³æã®äžã«èŠãããããããªæèšãããã
"èšåºæ€æ»å€è©äŸ¡ã§ã¯ãæäž1åç®ä»¥éããã¹ãŠã®å¹Žéœ¢ã»æäžçŸ€ã§èªããããäžéæ§ã®ãªã³ãçæžå°ããçŽ1é±é以å ã«æ¶å€±ããã»ã»ã»"
ã€ãŸãã1åç®ã®æ¥çš®åŸ1é±éã¯ããããã幎霢局ã®äººãäžéæ§ã®å ç«æå¶ãèšãæããã°ãäžæçãªå ç«åã®äœäžãçµéšããããšããã¡ã€ã¶ãŒç€Ÿã¯ç¥ã£ãŠããã®ã§ããã
Iversenãææããããã«ã1åç®ã®æ¥çš®ãã14æ¥åŸãŸã§ã¯éšåæ¥çš®ãšã¿ãªããã11ã2åç®ã®æ¥çš®ãã2é±éåŸã«ã¯æ£åŒã«å®å šæ¥çš®ãšãªãããããã®ããšãææçãæªããŠããå¯èœæ§ãããã
æåã®1é±éã¯ææããããã®ã«ããã®éã¯æªæ¥çš®ãšã«ãŠã³ãããããšãæªæ¥çš®ã®äººãææãããããã®ããã«èŠããããå®éã¯ããã§ã¯ãªãããã¡ã€ã¶ãŒç€Ÿãè¡ã£ã詊éšã§ã¯ãã¯ã¯ãã³æ¥çš®åŸ7æ¥ä»¥å ã«ããã©ã»ãçŸ€ã«æ¯ã¹ãã¯ã¯ãã³çŸ€ã§409人察287äººãšææã«ææãå€ãããšã瀺ãããŠããã
å®å šãªäºé²æ¥çš®ãåããæ¹ãCOVIDã§æ»äº¡ãã確çãé«ã
ãã¡ã€ã¶ãŒç€Ÿãšç±³åœé£åå»è¬åå±ãããã®æ³šå°ãå ç«æå¶ãåŒãèµ·ããããšãèªèããŠããããšã¯ãè±åœæ¿åºã®ããŒã¿ã«ãããšãæªæ¥çš®è ã«æ¯ã¹ãŠã2åæ¥çš®ãã人ã¯ãä»ãšãªã£ãŠã¯ãæçœªã®èšŒæ ãšãªãã
COVID-19ãšèšºæããã確çã¯æå€§3å
COVID-19ã§å ¥é¢ãã確çã2åé«ããªã
COVID-19ã§æ»äº¡ãã確çã3åã«ãªã
ãã¡ã€ã¶ãŒç€Ÿã®è³æã§ã¯ãååæäžåŸã«äžæçã«å ç«æ©èœãäœäžããããšã¯èªããŠãããã2åæ¥çš®ãã人ã®éã§ã³ããã«ããéçææçãæ»äº¡ã®ãªã¹ã¯ãé«ãŸã£ãŠããçŸå®ã®ããŒã¿ã¯ããã®åŸãå®éã«ADEãèµ·ãã£ãŠããå¯èœæ§ã瀺åããŠããã
Daily Exposeã2022幎第13é±ã®UKHSA Vaccine Surveillance ReportïŒ40ããŒãžãš45ããŒãžïŒã®ããŒã¿ã䜿ã£ãŠäœæããäžã®ã°ã©ãã¯ã誰ãCOVIDã«ããããããããæããã«ãããã®ã§ããããããŠãããªãã«ãã¯ã·ã³ã°ã®ææçã¯ããã«ãã¯ã·ã³ã°ãããããã«é«ããªã£ãŠããŸãã

次ã®å³ã¯ã41ããŒãžãš45ããŒãžã®ããŒã¿ã䜿ã£ãŠããDaily Expose16ããäœæãããCOVIDã®å ¥é¢çã®æ¯èŒã§ããã

ãããŠæåŸã«æ»äº¡çã®æ¯èŒã§ããã2022幎第13é±ã®UKHSAã¯ã¯ãã³ãµãŒãã€ã©ã³ã¹ã¬ããŒãã®44ããŒãžãš45ããŒãžãåèã«ããŸããã 40æ³ä»¥äžã§ããã«ãžã£ããåãã人ã¯ãåã幎霢ã®ã¯ã¯ãã³æªæ¥çš®è ãããCOVIDã§æ»äº¡ããå¯èœæ§ãé«ããªããŸããã

çŸå®äžçã«ãããè² ã®ã¯ã¯ãã³å¹æ
The Daily Exposeã¯ããã«ãCOVIDãžã£ãã®çŸå®äžçã§ã®æå¹çãèšç®ããã°ã©ãåããŠããããããã¯æ²æšãªãã¥ãŒã¹ã§ãã18ã
ãããã10äžäººåœããã®æå¹çã被æ¥çš®è ããé«ããã°ãããã¯Covid-19ã®æ³šå°ãçŸå®äžçã§ã¯è² ã®æå¹æ§ãæã€ããšã蚌æãããããšãæå³ããŸãããããŠããã¡ã€ã¶ãŒã®ã¯ã¯ãã³å¹æèšç®åŒã䜿ãã°ãå幎霢局ã«ãããçŸå®ã®å¹æãã©ã®çšåºŠãªã®ããæ£ç¢ºã«èªã¿åãããšãã§ããŸãã
ãã¡ã€ã¶ãŒã®ã¯ã¯ãã³èšç®åŒ 10äžäººåœããã®æªæ¥çš®ç-10äžäººåœããã®ã¯ã¯ãã³æ¥çš®çïŒ10äžäººåœããã®æªæ¥çš®çÃ100ïŒã¯ã¯ãã³å¹æ ...
ãã®ããŒã¿ã«ãããšã18æ³ä»¥äžã®äºéæ¥çš®è ã¯ãã¹ãŠ2åãã3åã®ç¢ºçã§ææãã18æ³ãã29æ³ã®ã¯ã¯ãã³å¹æã¯ãã€ãã¹87ïŒ ã80æ³ä»¥äžã®ã¯ã¯ãã³å¹æã¯ãã€ãã¹178ïŒ ãšãªã£ãŠããŸãã
30æ³ä»¥äžã®å šäºåæ¥çš®è ã¯ãå ¥é¢ãã確çã0.2åãã2åã«ãªãã30æ³ãã39æ³ã®ã¯ã¯ãã³å¹æã¯ãã€ãã¹1ïŒ ã80æ³ä»¥äžã®ã¯ã¯ãã³å¹æã¯ãã€ãã¹76ïŒ ãšãªãã
次ã®å³ã¯ãäžèšã®æ»äº¡çãããã€ã®ãªã¹ã®äºéæ¥çš®è ã®æ»äº¡ã«å¯ŸããçŸå®ã®COVID-19ã®ã¯ã¯ãã³å¹æã瀺ãããã®ã§ãã»ã»ã»ã
40æ³ä»¥äžã®ããã«ã¯ã¯ãã³æ¥çš®è ã¯ãã¹ãŠCOVID-19ã§æ»äº¡ãã確çã2åãã3åã«ãªãã30æ³ãã39æ³ã®ã¯ã¯ãã³å¹æã¯ãã€ãã¹90ïŒ ã80æ³ä»¥äžã®ã¯ã¯ãã³å¹æã¯ãã€ãã¹156ïŒ ãšãªã£ãŠããŸãã"

ãã¡ã€ã¶ãŒç€ŸãåäŸã®ãªãå ±åæžã®åŠçã«600人ãéçš
ãã®2幎éãç§ãã¡ã¯ç±³åœã®ã¯ã¯ãã³æå®³äºè±¡å ±åã·ã¹ãã ïŒVAERSïŒã泚èŠããæ¯é±æ°çŸä»¶ãã€å¢å ããéå»32幎éã«ä»ã®ãã¹ãŠã®ã¯ã¯ãã³ãåãããå·å®³ãæ¥éã«äžåããä¿¡ããããªãæãã§é ãæ¯ã£ãŠããŸããã
2022幎3æ25æ¥çŸåšãCOVIDãžã£ãé¢é£ã®å ±åã¯1,205,753ä»¶ããã¡å ¥é¢ã¯145,781ä»¶ãæ»äº¡ã¯26,396ä»¶ãšãªã£ãŠããŸã20ããããã®å®éšçãªæ³šå°ã»ã©ãå·å®³çã§èŽæ»çãªãã®ã¯ãªãã®ã§ãã
2020幎12æãã2021幎2ææ«ãŸã§ã®éã«ããã¡ã€ã¶ãŒã¯å šäžçã§126,212,580ååã®mRNAãžã£ããåºè·ããŠããŸãã158,000ã®å¯äœçšã§å²ããšã1åãããã®æå®³äºè±¡çºççã¯ã»ãŒ1:800ãšãªãã
以åã®ææžã§ã¯ããã¡ã€ã¶ãŒã¯ãå±éã®æåã®3ã¶æã§åèš158,893ã®ã€ãã³ããå«ã42,086ã®ã±ãŒã¹ã¬ããŒããåãåã£ãããšãããããŸããããã®ãªãªãŒã¹ã§ã¯ãåºè·ãããæçšåæ°ãç·šéãããŠããŸãããã2022幎4æ1æ¥ã®ãªãªãŒã¹ã§ã¯ç·šéãããã«æ®ã£ãŠããããããã®æåã®3ã«æéã«ãã¡ã€ã¶ãŒã«å ±åãããæå®³äºè±¡ã®å²åãèšç®ã§ããããã«ãªã£ããšããããšã§ãã
2020幎12æãã2021幎2ææ«ãŸã§ã®éã«ããã¡ã€ã¶ãŒã¯å šäžçã§1å2621äž2580ååã®mRNAãžã£ããåºè·ããŠããŸãã158,000ä»¶ã®å¯äœçšã§å²ããšã1åãããã®æå®³äºè±¡çºççã¯ã»ãŒ800åã®1ãšããããšã«ãªã21ãããã¯ãã¡ããã¡ãç¡è²¬ä»»ã§ãã
ãŸãããã¡ã€ã¶ãŒç€Ÿã¯2021幎2ææ«ãŸã§ã«ãåäŸã®ãªãã»ã©æ®ºå°ããæå®³äºè±¡å ±åãåŠçããããã«600人ã®ãã«ã¿ã€ã åŸæ¥å¡ã远å éçšãã2021幎6ææ«ãŸã§ã«1800人以äžãéçšããããšã«ãªããšäºæž¬ããŠããããšããçŸåšãææžã§ç¢ºèªãããŠããŸã22ã
çµå±ãã³ãããžã£ãã¯ã補è¬äŒç€ŸãšèŠå¶åœå±ã®äž¡æ¹ãé²ãã§åå ããå²äžæå€§ã®å»çé誀ãšããŠæŽå²ã«å»ãŸããããšã«ãªãã®ã ããããããŠãçµãããèŠããªãã
2022幎3æãFDAã¯ãã¢ããã®4åç®ã®æ³šå°ã®å¹æã¯11ïŒ ã§ãåãã人ã®40ïŒ ã«å¯äœçšãçãããã¡ã€ã¶ãŒã®4åç®ã®æ³šå°ã®å¹æã¯30ïŒ ã§ã80ïŒ ã«å¯äœçšãçãããšãããã¬ããªã³ãç ç©¶23ïŒ24ã«åºã¥ããŠãå ã«4åç®ãš5åç®ãèªå¯ããã
ãã®å ¬è¡è¡çã®æªå€¢ãçµããã責任è ããã®ç¯çœªçé倱ã®è²¬ä»»ãåãããã®ã«ãäœãå¿ èŠãã¯ããããªãããã©ãããããŸã æãã®èšçç¹ã«ã¯éããŠããªãããã§ããã
åºå žã»åèæç®
1, 12 The Naked Emperor Substack March 29, 2022
5, 6 5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports, Page 11, Table 5
7, 8, 10, 13, 14, 16, 18 Daily Expose April 3, 2022
19, 21, 22 The Defender April 5, 2022
23 MedRxiv February 15, 2022, DOI: 10.1101/2022.02.15.22270948
24 NEJM Correspondence March 16, 2022 DOI: 10.1056/NEJMc2202542